EGFR and non-small cell lung carcinoma: Although our sample was likely enriched for targetable mutations (such as EGFR and ALK rearrangements), it remains a close representation of the real-world stage III NSCLC patient population treated at specialized cancer centers, with adenocarcinoma and squamous cell carcinoma histology subtypes comprising 60% and 33% of our cohort respectively.